Greenwich LifeSciences, Inc.
GLSIGreenwich LifeSciences, Inc. (GLSI) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company specializes in advancing innovative treatments, including vaccines designed to stimulate the immune system against specific tumor-associated antigens. Its pipeline primarily targets breast and other solid tumors.
Company News
Greenwich LifeSciences provided updates on its Phase III FLAMINGO-01 clinical trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company reported that the 250-patient non-HLA-A*02 arm is fully enrolled with preliminary data showing approximately 80% reduction in recurrence rates. The company is implementing cost reduct...
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator ...
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
